Last reviewed · How we verify

epinephrine and levosimendan

Federal University of Juiz de Fora · FDA-approved active Small molecule

epinephrine and levosimendan is a Inotropic agent combination Small molecule drug developed by Federal University of Juiz de Fora. It is currently FDA-approved for Acute decompensated heart failure with cardiogenic shock, Acute heart failure requiring inotropic support.

This combination uses epinephrine's alpha and beta-adrenergic stimulation alongside levosimendan's calcium sensitization to enhance cardiac contractility and improve hemodynamics in acute heart failure.

This combination uses epinephrine's alpha and beta-adrenergic stimulation alongside levosimendan's calcium sensitization to enhance cardiac contractility and improve hemodynamics in acute heart failure. Used for Acute decompensated heart failure with cardiogenic shock, Acute heart failure requiring inotropic support.

At a glance

Generic nameepinephrine and levosimendan
SponsorFederal University of Juiz de Fora
Drug classInotropic agent combination
TargetAdrenergic receptors (alpha-1, beta-1) and cardiac troponin C
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Epinephrine acts as a catecholamine agonist, increasing heart rate and contractile force through beta-1 adrenergic receptors while also providing vasoconstriction via alpha-1 receptors. Levosimendan is an inodilator that increases myocardial contractility by sensitizing cardiac troponin C to calcium without increasing oxygen consumption, while simultaneously causing vasodilation. Together, they provide both inotropic support and hemodynamic improvement in cardiogenic shock or acute decompensated heart failure.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about epinephrine and levosimendan

What is epinephrine and levosimendan?

epinephrine and levosimendan is a Inotropic agent combination drug developed by Federal University of Juiz de Fora, indicated for Acute decompensated heart failure with cardiogenic shock, Acute heart failure requiring inotropic support.

How does epinephrine and levosimendan work?

This combination uses epinephrine's alpha and beta-adrenergic stimulation alongside levosimendan's calcium sensitization to enhance cardiac contractility and improve hemodynamics in acute heart failure.

What is epinephrine and levosimendan used for?

epinephrine and levosimendan is indicated for Acute decompensated heart failure with cardiogenic shock, Acute heart failure requiring inotropic support.

Who makes epinephrine and levosimendan?

epinephrine and levosimendan is developed and marketed by Federal University of Juiz de Fora (see full Federal University of Juiz de Fora pipeline at /company/federal-university-of-juiz-de-fora).

What drug class is epinephrine and levosimendan in?

epinephrine and levosimendan belongs to the Inotropic agent combination class. See all Inotropic agent combination drugs at /class/inotropic-agent-combination.

What development phase is epinephrine and levosimendan in?

epinephrine and levosimendan is FDA-approved (marketed).

What are the side effects of epinephrine and levosimendan?

Common side effects of epinephrine and levosimendan include Tachycardia, Hypertension, Arrhythmias, Tremor, Headache.

What does epinephrine and levosimendan target?

epinephrine and levosimendan targets Adrenergic receptors (alpha-1, beta-1) and cardiac troponin C and is a Inotropic agent combination.

Related